Bionanotechnology and microfluidics provide the foundations for GeneFluidics' testing platform. The use of bionanotechnology drives high signal to noise ratios (sensitivity), while the incorporation of microfluidics permits operational simplicity.
Genetix is an independent business unit within Leica Microsystems. The company provides scientists and clinicians with unrivalled solutions for imaging and intelligent image analysis in the life science and clinical markets.
Genovis has a broad knowledge within physics, biology and biochemistry and offers nanoparticles as tools in medical imaging and for in vitro/in vivo transfections. We have developed a new category of nanoparticles that generate a contrast effect in more than one type of medical imaging technique and offer customer made nanoparticles which besides the particles per se also include method development and services in the form of pre-studies that are specifically adapted to the individual needs of the customer.
Genovoxx is developing a technology for the massively parallel sequencing by synthesis of nucleic acids. This technology enables the sequencing of many millions of nucleic acids molecules in parallel format at the single molecule level.
One of the world's foremost biotechnology companies, the company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing.
The company's focus is on the rapidly emerging field of nanobiotechnology with an emphasis on the early detection and localization of cancer and other human diseases. Their technologies also hold the promise of providing image-guided therapy for the treatment of these diseases, as well as providing new methods for therapeutic intervention.
(German language site) The company is a Contract Research Organisation for the development and improvement of advanced cell culture systems for industrial drug screening applications, biomaterial testing and pharma-toxicological research.
A spin off founded to commercialize FDEC FET nano sensor technology invented at Arizona State University.The novel nano sensor technology is capable of exponential capacitive transduction for ultra high sensitivity molecular detection, coupled with exceptional selectivity.
Inanovate creates nano-scale surface structures through a unique and proprietary process capable of nano-meter precision in a time and cost effective way. Leveraging this unique platform and expertise, Inanovate is developing nano-structured biochip substrates to facilitate the next generation in biochip technology.
The company is engaged in R&D and production of nanomaterials and nanomaterials production equipment. Production program covers mostly antibacterial products for healthcare (patches, bandages), hygiene (insoles), cleaning and food industry. The company also produces unique machines for polymerisation of nanolayers at textile materials 'INM Foulard' and exclusively distributes unique patented electrospinning devices 'MultiSpin' and electrospinning devices clima control units 'ClimaSpin'.
The company's lead product in development is Amorphous Nano-Hydroxyapaite Powder. Nano-structured hydroxyapatite has several advantages over hydroxyapatite of larger particle size in its use in bone tissue engineering due to its higher surface area and consequently higher reactivity, which offers better cellular response. In addition, nano-sized hydroxyapatite is useful as an effective surface modification agent for binding numerous biological molecules.
The company specializes in providing protein engineering to pharmaceutical and biotechnology companies for the discovery, identification and design of new peptide, polypeptide, protein and antibody compounds using their proprietary technology.
Primary goals of the company are the development and the establishment of innovative bioinstrumentation based on Femtosecond Laser Technology for biotechnology, cell biology and medicine, e.g. nanoprocessing with femtosecond near infrared laser pulses.
Keystone Nano has an exclusive license to Penn State patented technology that allows the creation of stable, non-toxic, 5 to 50 nm-composite particles that they call Molecular Dots (MDs). These Molecular Dots can encapsulate drugs and/or fluorescent molecules.